Importantly, EAT could also represent a novel therapeutic target: because of its rapid metabolism and potential for modification, targeting EAT with drugs such as glucagon-like peptide 1 and sodium-glucose cotransporter-2 inhibitor agonists may reshape the landscape of pharmacotherapy, providing cardiovascular protection beyond just SSc management. The gene discussed is SLC5A2; the disease is systemic sclerosis.